Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
-
Fibrocell Science (FCSC) Announces Pact with Castle Creek Pharma to Develop and Commercialize FCX-007 Gene Therapy
-
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy
-
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy
-
Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights
-
Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights
-
Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights
-
Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights
-
Fibrocell Announces Review of Strategic Alternatives
-
Fibrocell Science (FCSC) to Review Strategic Alternatives
-
Fibrocell Announces Review of Strategic Alternatives
-
Fibrocell Announces Review of Strategic Alternatives
-
Fibrocell Science (FCSC): Raising PT to $7 Ahead of RDEB Ph1 Results - Canaccord
-
Fibrocell to Present at Canaccord Genuity 37th Annual Growth Conference